.avif)
Galapagos Email Format
Biotechnology Research
・
201-500 employees
・
Mechelen, Belgium
Galapagos is a biotechnology company with operations in the U.S., Europe, and Asia, dedicated to developing transformational medicines through innovative science and decentralized cell therapy manufacturing.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@glpg.com
Company Overview
Industry
Biotechnology Research
Founded
1999
Headquarters
Mechelen, Belgium
Revenue
$250M-$500M
FUNDING Stage
Public
Website
Key Executives
Henry Gosebruch (Executive Director and Chief Executive Officer), Aaron Cox (Chief Financial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Galapagos?
Galapagos uses the first.last format, so Jane Smith would be jane.smith@glpg.com.
What therapeutic areas does Galapagos focus its drug development on?
Galapagos focuses its pipeline on oncology and immunology and inflammation. The company pursues a modality-agnostic strategy, targeting biologics, bispecific antibodies, ADCs, and small molecules with clear clinical proof-of-concept in those two areas.
How can I find and verify a Galapagos contact for outreach or prospecting?
Since Galapagos uses the first.last@glpg.com format, you can build an address if you know a contact's name. Tools like Clay can help you verify those addresses, enrich contact records, and identify the right people across Galapagos's small, focused team of around 767 employees.
What is Galapagos's collaboration with Gilead Sciences on OM336 in 2026?
In March 2026, Galapagos announced a co-development partnership with Gilead on OM336 (gamgertamig), a first-in-class BCMAxCD3 bispecific T-cell engager for autoimmune diseases. Galapagos will co-fund development costs and receive royalties of 20 to 23 percent on net sales.
Who leads Galapagos as CEO in 2026?
Henry Gosebruch serves as Executive Director and Chief Executive Officer of Galapagos in 2026. He took on the role in May 2025 and is steering the company toward a business development-led strategy in oncology and immunology and inflammation.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating